TOP TEN perturbations for 3501 (Homo sapiens)

Organism: Homo sapiens
Gene: 3501
Selected probe(set): 211430_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 3501 (211430_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):8.644787
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

inclusion body myositis study 1 / normal biceps tissue

Relative Expression (log2-ratio):7.9796286
Number of Samples:5 / 3
Experimental inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal biceps tissue
Biceps femoris biopsy muscle samples from control subjects.

multiple sclerosis study 3 (relapse) / unaffected CSFC sample

Relative Expression (log2-ratio):7.874902
Number of Samples:11 / 18
Experimental multiple sclerosis study 3 (relapse)
Cerebrospinal fluid cell (CSFC) samples from patients with diagnosed relapse-remitting Multiple Sclerosis (RR-MS). Samples were taken during relapse initiated no more than two weeks earlier.
Control unaffected CSFC sample
Cerebrospinal fluid cell (CSFC) samples from patients with a non-inflammatory neurological disease (psychosis, vertigo, paresthesia, cervical spinal stenosis, ependymoma, headache, hereditary spastic paresis, migraine, muscle pain, neurasthenia, sensory symptoms, vertebral dissection or dissociative motor disorder). Patients were unaffected of multiple sclerosis.

rheumatoid arthritis study 1 / normal synovial membrane tissue

Relative Expression (log2-ratio):7.43223
Number of Samples:5 / 6
Experimental rheumatoid arthritis study 1
Synovial membrane tissue from patients with rheumatoid arthritis.
Control normal synovial membrane tissue
Normal synovial membrane tissue.

Rosacea study 1 (PhR) / normal skin tissue

Relative Expression (log2-ratio):7.3966293
Number of Samples:12 / 20
Experimental Rosacea study 1 (PhR)
Skin biopsy samples from patients with phymatous rosacea (PhR), diagnosed in accordance with classification system of the American Rosacea Society. Skin biopsies were taken from nasolabial fold.
Control normal skin tissue
Normal skin biopsy samples from healthy individuals.

necrotizing myopathy study 1 / inclusion body myositis study 1

Relative Expression (log2-ratio):-6.9492407
Number of Samples:3 / 5
Experimental necrotizing myopathy study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

multiple sclerosis study 10 (PP-MS) / cerebrospinal fluid cell sample (mixed neuropathologies)

Relative Expression (log2-ratio):6.862796
Number of Samples:10 / 9
Experimental multiple sclerosis study 10 (PP-MS)
Cerebrospinal fluid (CSF) cell samples from patients with primary progressive multiple sclerosis (PP-MS). Active disease was defined by the presence of any of the following criteria during 6 month prior CSF collection: (1) one or more relapses, (2) change of 0.5 point or greater in EDSS (Expanded Disability Status Score), (3) change in the number and size of lesions visualized by gadolinium-enhanced MRI. Untreated MS patients did not receive any medication for at least 1 year before CSF sample collection.
Control cerebrospinal fluid cell sample (mixed neuropathologies)
Cerebrospinal fluid (CSF) cell samples from patients with different neuropathologies, other than multiple sclerosis.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):6.762517
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

necrotizing myopathy study 2 / inclusion body myositis study 2

Relative Expression (log2-ratio):-6.588049
Number of Samples:2 / 5
Experimental necrotizing myopathy study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).

MEDI-551 study 3 (3 mg/kg) / scleroderma study 4 (placebo; 85d)

Relative Expression (log2-ratio):-6.2924404
Number of Samples:3 / 4
Experimental MEDI-551 study 3 (3 mg/kg)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous injection of MEDI-551 (3 mg/kg), an anti-CD19 monoclonal antibody. ATC code:---
Control scleroderma study 4 (placebo; 85d)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous placebo treatment. ATC code:---